Primary pediatric live‐donor‐kidney transplant‐recipients' outcomes by immunosuppression induction received in the United States. (17th December 2020)

• Record Type: Journal Article
• Authors: Riad, Samy; Jackson, Scott; Chinnakotla, Srinath; Verghese, Priya
• Is Part Of: Pediatric transplantation. Volume 25:Number 5(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-12-17
• Subjects: induction -- kidney transplant -- living Donor -- pediatric; Transplantation of organs, tissues, etc. in children -- Periodicals; 617.95408305
• DOI: 10.1111/petr.13925
• Languages: English
• ISSNs: 1397-3142

Abstract

Abstract: Objective: We examined the association between induction type and outcomes of live‐donor pediatric kidney recipients on tacrolimus and mycophenolate maintenance. Material and Methods: We analyzed the SRTR standard analysis file to evaluate primary live‐donor pediatric kidney recipients between 2000 and 2018. Recipients were grouped by induction type into three groups: alemtuzumab n = 289, anti‐thymocyte n = 1197, and IL‐2RA n = 1625. Kaplan‐Meier curves were generated for recipient and death‐censored graft survival. Predictors of recipient and allograft survival were examined using Cox proportional hazards models. Models were adjusted for age, sex, ethnicity, renal failure etiology, HLA‐mismatches, transplant year, steroid maintenance, preemptive transplantation, payor type, and donor factors such as age, sex, and donor‐recipient relationship. The transplant center was included as a random effect to account for inter‐center variability. Results: Rejection rates at 6 months (Alemtuzumab 9.5% vs. r‐ATG 5.7% vs. IL2‐RA 5.3%; P : .023) and 12 months (Alemtuzumab 14.5% vs. r‐ATG 10.8% vs. IL2‐RA 9%; P : .028) were significantly higher in the alemtuzumab group. PTLD rate (Alemtuzumab 0.8% vs. r‐ATG 2.2% vs. IL2‐RA 1%; P : .028) was significantly higher in the anti‐thymocyte group. In the multivariable models, induction type did not influence patient or death‐censored graft survival within ten years post‐transplant. Conclusion: In this large cohort of standard immunological risk primary pediatric live‐donor kidney recipients, as compared to IL‐2RA, neither alemtuzumab nor anti‐thymocyte globulin was associated with improved long‐term graft or recipient survival. In the first year post‐transplant, recipients of alemtuzumab induction had a higher rejection rate, while PTLD was more frequently observed in the anti‐thymocyte recipients. Abstract : Primary Pediatric Liver Donor Outcome by Induction Type. Visual Abstract by Samy Riad, MD, MS